CRIZANLIZUMAB
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$1.8M
Transactions
411
Doctors
53
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.8M | 380 | 49 |
| 2017 | $21,491 | 31 | 15 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 68 | 77.3% |
| Consulting Fee | $333,805 | 74 | 18.1% |
| Travel and Lodging | $56,814 | 173 | 3.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $15,044 | 5 | 0.8% |
| Food and Beverage | $8,170 | 90 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,775 | 1 | 0.2% |
Payments by Type
Research
$1.4M
68 transactions
General
$417,608
343 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE II MULTICENTER STUDY TO CONFIRM PK PD OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN ADULT SICKLE CELL DISEASE PATIENTS WITH HISTORY OF VOC | Novartis Pharmaceuticals Corporation | $1.3M | 0 |
| A MULTICENTER RETROSPECTIVE NON INTERVENTIONAL FOLLOW UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISIS WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES | Novartis Pharmaceuticals Corporation | $68,550 | 0 |
| A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN SEQUENTIAL DESCENDING AGE GROUPS OF PEDIATRIC SICKLE CELL DISEASE PATIENTS WITH VASO OCCLUSIVE CRISIS | Novartis Pharmaceuticals Corporation | $24,219 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $16,124 | 8 |
| A PHASE I SINGLE DOSE RANDOMIZED OPEN LABEL PARALLEL GROUP SINGLE CENTER TRIAL TO ASSESS THE COMPARABILITY OF CRIZANLIZUMAB PHARMACOKINETICS AND PHARMACODYNAMICS ADMINISTERED AS SEG101 IN COMPARISON TO SELG1 IN HEALTHY VOLUNTEERS | Novartis Pharmaceuticals Corporation | $13,406 | 0 |
| A MULTICENTER RETROSPECTIVE NON INTERVENTIONAL FOLLOW UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISIS WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES | NOVARTIS PHARMACEUTICALS CORPORATION | $8,488 | 0 |
| A PHASE II MULTICENTER RANDOMIZED PLACEBO CONTROLLED DOUBLE BLIND 12 MONTH STUDY TO ASSESS SAFETY AND EFFICACY OF SELG1 WITH OR WITHOUT HYDROXYUREA THERAPY IN SICKLE CELL DISEASE PATIENTS WITH SICKLE CELL RELATED PAIN CRISES | Novartis Pharmaceuticals Corporation | $4,498 | 0 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,875 | 1 |
| A PHASE II MULTICENTER STUDY TO CONFIRM PK PD OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN ADULT SICKLE CELL DISEASE PATIENTS WITH HISTORY OF VOC | NOVARTIS PHARMACEUTICALS CORPORATION | $1,044 | 0 |
| A PHASE I SINGLE DOSE RANDOMIZED OPEN LABEL PARALLEL GROUP SINGLE CENTER TRIAL TO ASSESS THE COMPARABILITY OF CRIZANLIZUMAB PHARMACOKINETICS AND PHARMACODYNAMICS ADMINISTERED AS SEG101 IN COMPARISON TO SELG1 IN HEALTHY VOLUNTEERS | NOVARTIS PHARMACEUTICALS CORPORATION | $800.00 | 1 |
| A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN SEQUENTIAL DESCENDING AGE GROUPS OF PEDIATRIC SICKLE CELL DISEASE PATIENTS WITH VASO OCCLUSIVE CRISIS | NOVARTIS PHARMACEUTICALS CORPORATION | $109.50 | 0 |
Top Doctors Receiving Payments for CRIZANLIZUMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $1.4M | 43 |
| , MD | Pediatric Hematology-Oncology | Birmingham, AL | $49,083 | 35 |
| , MD | Pediatrics | Charlotte, NC | $43,200 | 30 |
| , MD | Hematology & Oncology | Farmington, CT | $30,250 | 21 |
| , MD | Pediatric Hematology-Oncology | Washington, DC | $29,626 | 23 |
| , M.D | Pediatrics | Dallas, TX | $25,326 | 23 |
| , M.D | Hematology & Oncology | Atlanta, GA | $18,728 | 17 |
| , MD | Hematology & Oncology | Augusta, GA | $17,586 | 17 |
| , MD | Pediatric Hematology-Oncology | Boston, MA | $16,232 | 13 |
| , MD | Internal Medicine | Memphis, TN | $14,109 | 11 |
| , MD | Internal Medicine | Durham, NC | $13,534 | 20 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $13,083 | 12 |
| , M.D | Internal Medicine | Richmond, VA | $11,966 | 7 |
| , MD | Hematology & Oncology | Aurora, CO | $10,293 | 6 |
| , M.D | Pediatrics | Atlanta, GA | $9,456 | 6 |
| , MD, PHD | Hematology & Oncology | Atlanta, GA | $9,310 | 6 |
| , MD | Pediatric Hematology-Oncology | Flint, MI | $9,099 | 8 |
| , M.D | Pediatric Hematology-Oncology | Woodbine, MD | $8,271 | 8 |
| , MD | Pediatric Hematology-Oncology | Greenville, NC | $8,021 | 7 |
| , M.D | Hematology | Durham, NC | $7,312 | 8 |
| , M.D | Pediatric Hematology-Oncology | Greenville, SC | $6,991 | 4 |
| , DO | Pediatric Hematology-Oncology | Birmingham, AL | $6,944 | 6 |
| , M.D | Hematology & Oncology | Ocala, FL | $6,653 | 6 |
| , M.D | Hematology & Oncology | Livingston, NJ | $6,550 | 1 |
| , MD | Pediatric Hematology-Oncology | Charleston, SC | $6,548 | 7 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.8M
- Total Doctors 53
- Transactions 411
About CRIZANLIZUMAB
CRIZANLIZUMAB is a biological associated with $1.8M in payments to 53 healthcare providers, recorded across 411 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $1.8M was paid across 380 transactions to 49 doctors.
The most common payment nature for CRIZANLIZUMAB is "Unspecified" ($1.4M, 77.3% of total).
CRIZANLIZUMAB is associated with 11 research studies, including "A PHASE II MULTICENTER STUDY TO CONFIRM PK PD OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN ADULT SICKLE CELL DISEASE PATIENTS WITH HISTORY OF VOC" ($1.3M).